| answer text |
<p>Departmental officials are in regular contact with colleagues in the National Institute
for Health and Care Excellence (NICE) and NHS England about a range of issues, including
progress in discussions about a potential managed access agreement for Spinraza (nusinersen).
Ministers have also held meetings with Biogen, NICE and NHS England on a number of
occasions, at which the availability of Spinraza was discussed.</p><p>NHS England
and NICE have made stakeholders and the public aware of the outcome of its appraisal
committee meeting and NICE is now able to recommend the use of Spinraza for National
Health Service patients in England, subject to a managed access agreement agreed between
NHS England and Biogen. The final appraisal document will be published in due course.</p><p>
</p>
|
 |
